HBK Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

HBK Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-19,000	Closed	-$1.28M	–	668
2019 Q3	$1.28M	Sell	19,000 -17,700	-48%	-$1.36M	0.02%	469
2019 Q2	$3.14M	Buy	+36,700	New	+$3.14M	0.03%	304
2013 Q4	–	Sell	-8,600	Closed	-$621K	–	896
2013 Q3	$621K	Sell	8,600 -6,900	-45%	-$459K	0.01%	582
2013 Q2	$865K	Buy	+15,500	New	+$966K	0.01%	443

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

HBK Investments's BMRN Position: Q4 2019 in Review

HBK Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 19,000 shares — an estimated $1.28M sold.

HBK Investments first reported a position in BMRN in Q2 2013 and held it in 4 quarters. The position peaked at $3.14M in Q2 2019. 468 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

HBK Investments reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
HBK Investments sold 19,000 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $1.28M.
HBK Investments first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 4 quarters.
HBK Investments's BioMarin Pharmaceuticals position peaked at $3.14M in Q2 2019.
468 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on HBK Investments's 13F filing for Q4 2019, filed 14 Feb 2020.